INMUNEBIO XPRO-1595

Drug Development Trials

About the trial

Phase 1b Open-Label, Dose-Identification Study of XPro1595 in Patients with Mild to Moderate Alzheimer’s Disease with Elevated high sensitivity C-reactive protein in blood.